Childhood Cancer Research

Share

Too many types of childhood cancer still have no known cure or treatment. In 2017, more than 15,000 children under age 19 will be diagnosed with cancer. 

We must ensure that researchers have the essential tools to fight childhood cancer and make sure children with cancer not only survive, but thrive. 

 

Over 15,000 U.S. children under age 19 will be diagnosed with cancer in 2017.

Take Action

Photo of children playing together

Help end childhood cancer

Cancer is the leading cause of death among children ages 1-19. Ask your U.S. Representative to pass the STAR Act.

Latest Updates

April 18, 2018
Oklahoma

As a child, she struggled with low platelet and red blood cell counts — an unusual combination of anemia in children. Doctors kept an eye on her health, and it would be three years before a genetic test of her bone marrow identified a duplicate chromosome that would ultimately lead to her Myelodysplastic Syndrome (MDS). If untreated, MDS becomes leukemia.

March 23, 2018
National

The U.S. Senate passed the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act. The bipartisan bill would advance pediatric cancer research and increase transparency and expertise for pediatric cancer research at the National Institutes of Health (NIH).

March 23, 2018
National

The U.S. Senate just passed the STAR Act, a bipartisan bill that lays the groundwork for new breakthroughs in researching and treating childhood cancer.

March 22, 2018
National

Tonight the U.S. Senate passed the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act. The bipartisan bill would advance pediatric cancer research and increase transparency and expertise for pediatric cancer research at the National Institutes of Health (NIH).

Childhood Cancer Research Resources

ACS CAN’s official endorsement of the RACE for Children Act, a bill that will encourage new research and development in childhood cancer.

This report examines the drug development landscape for childhood cancer, identifying scientific, logistical, economic and ethical challenges that are unique to pediatric cancer drug development.